Yahoo · Sep 21, 2026
Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode
Soon-Shiong owned 65.5% of ImmunityBio as of its April proxy record date.
IB
NASDAQ · IBRX
ImmunityBio, Inc.
Healthcare · Biotechnology
$8.45
Up+$0.49 (+5.77%)
Updated Sep 22, 2026, 4:01 PM
SID Score
6.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.16B
- P/E ratio
- -5.96
- Dividend yield
- 0.00%
- 52-week range
- $1.95 – $12.43
- Volume
- 12.24M
- Avg. volume
- 10.1M
Price performance
IBRX price history
1M range · 20 trading sessions · Daily adjusted prices
IBRX closed at $8.45 after 20 trading sessions, up 11.48% for the selected period.
- Last close
- $8.45
- Period change
- +11.48%
- Period low
- $7.58
- Period high
- $8.48
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 21, 2026 | $8.72 | $8.87 | $8.26 | $8.45 | 12.24M |
| Sep 18, 2026 | $8.46 | $8.53 | $8.20 | $8.48 | 18.43M |
| Sep 17, 2026 | $8.14 | $8.80 | $8.12 | $8.46 | 19.16M |
| Sep 16, 2026 | $8.135 | $8.30 | $7.76 | $7.91 | 9.2M |
| Sep 15, 2026 | $8.32 | $8.34 | $7.85 | $8.14 | 8.95M |
| Sep 14, 2026 | $7.89 | $8.40 | $7.87 | $8.37 | 9.16M |
| Sep 11, 2026 | $7.80 | $8.345 | $7.80 | $7.91 | 12.47M |
| Sep 10, 2026 | $7.87 | $7.89 | $7.64 | $7.72 | 8.81M |
| Sep 9, 2026 | $8.22 | $8.36 | $7.875 | $8.06 | 9.49M |
| Sep 8, 2026 | $8.00 | $8.37 | $7.93 | $8.29 | 7.74M |
| Sep 4, 2026 | $8.08 | $8.24 | $8.01 | $8.08 | 4.33M |
| Sep 3, 2026 | $8.00 | $8.21 | $7.88 | $8.19 | 5.27M |
| Sep 2, 2026 | $7.945 | $8.28 | $7.755 | $7.95 | 7.23M |
| Sep 1, 2026 | $7.82 | $7.99 | $7.73 | $7.87 | 6.47M |
| Aug 31, 2026 | $7.88 | $8.0195 | $7.84 | $7.95 | 6.88M |
| Aug 28, 2026 | $8.31 | $8.3199 | $7.945 | $8.05 | 7.98M |
| Aug 27, 2026 | $8.24 | $8.76 | $8.18 | $8.40 | 12.31M |
| Aug 26, 2026 | $8.17 | $8.40 | $8.07 | $8.25 | 9.45M |
| Aug 25, 2026 | $7.69 | $8.23 | $7.68 | $8.19 | 11.55M |
| Aug 24, 2026 | $7.68 | $7.72 | $7.46 | $7.58 | 5.67M |
Latest IBRX news
The latest Smart Investors Daily articles mentioning IBRX.
Stock researchCompany · Overview
IBRX research
Overview
Company profile and research snapshot.
Company profile
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | Buy | — |
| May 21, 2026 | BTIG | Buy | — |
| May 20, 2026 | HC Wainwright & Co. | Buy | — |
| May 5, 2026 | D. Boral Capital | Buy | — |
| Apr 21, 2026 | D. Boral Capital | Buy | — |
News briefing
Generated Sep 22, 2026, 3:15 PM
Why Is IBRX Up Today?
ImmunityBio shares gained 4.32% today as founder speculation around potential tokenization of the company's stock sparked renewed investor interest and trading activity. The teased possibility of converting IBRX into a tokenized security has ignited speculation among retail traders, driving modest upside momentum in what appears to be a sentiment-driven move rather than fundamental news.
Bottom line: Today's gain appears driven by tokenization speculation rather than fundamental developments, making it a sentiment-based move that may lack staying power without concrete announcements. Investors should await official guidance on tokenization plans while remaining focused on IBRX's core immunotherapy pipeline and financial position as the primary drivers of long-term value.
Yahoo · Sep 18, 2026
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Yahoo · Sep 16, 2026
ImmunityBio (IBRX) Moved, So What Is Drawing Fresh Attention?
Nant Capital’s investment of up to $22.3 million in a PIPE into PDS Biotech, along with Patrick Soon Shiong’s new board seat there, pushed ImmunityBio (NasdaqGS:IBRX) up 6% on Monday and sharpened focus on his broader immunotherapy plans. ImmunityBio’s share price has cooled slightly in the very short term, with a 1-day share price return of 2.75% and a 7-day share price return of 1.81%. However, the 30-day and 90-day share price returns of 7.53% and 16.45% suggest momentum is still building...
Yahoo · Sep 15, 2026
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
